Biotechnology startup Intero Biosystems has won the Startup Battlefield competition at TechCrunch Disrupt 2026, earning recognition for its approach to studying how drugs and other compounds affect human biology.
The Denver-based company was selected as the winner after competing against other startups at the event in San Francisco. The competition’s top teams presented live demonstrations to judges from the investment and technology industries, with the winner receiving a $100,000 prize.
Intero’s victory highlights how technology competitions are increasingly giving attention to companies working in scientific research and healthcare, not only consumer apps and software platforms.
Using Lab-Grown Human Tissue for Research
Intero Biosystems is developing small human intestinal organoids — lab-grown tissue structures designed to mimic aspects of the human gut.
These structures can help researchers investigate how substances interact with human intestinal tissue. The company says its flagship product, GastroScreen, is intended for pharmaceutical, biotechnology, food and chemical companies that need to evaluate drugs and other compounds.
Testing substances before they reach human trials is an important part of research and development. Existing approaches can involve laboratory cell models, animal studies and other experimental methods, each with its own strengths and limitations.
Human tissue models may provide additional information about how compounds behave in a biological environment. However, laboratory models do not fully reproduce the complexity of a living human body, and their results must be interpreted alongside other evidence.
Why the Technology Could Matter
Drug development is expensive and uncertain. Researchers must identify promising candidates, assess potential safety problems and gather evidence before a treatment can progress through the stages of clinical testing.
Tools that provide more useful information earlier in this process could help researchers prioritise candidates and improve experimental design.
Intero’s approach may also be relevant beyond pharmaceuticals. Companies developing food ingredients or chemical products may need to evaluate how substances interact with biological systems.
The potential value will depend on the reliability of the models, the quality of the resulting data and whether customers can incorporate the technology into established research workflows.
Why Startup Competitions Matter
Startup Battlefield provides young companies with a platform to present their products to investors, industry experts and potential partners.
Winning can increase visibility, create networking opportunities and help a company attract attention from future customers or investors. The prize money can also support product development and business operations.
Nevertheless, a competition victory does not guarantee commercial success. Intero will still need to demonstrate the value of its technology, build customer relationships and navigate the scientific and regulatory requirements associated with its field.
The Future of Biotech Innovation
Intero’s win is a reminder that important technology developments are taking place outside the most visible areas of consumer electronics and artificial intelligence.
Advances in biotechnology can influence medicine, food science and chemical research, potentially creating new tools for problems that have resisted conventional approaches.
For Intero Biosystems, the next challenge is turning recognition into measurable progress in research and commercial adoption.
